Across TCGA pan-cancer cohorts, FTLP16 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of FTLP16’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where FTLP16 RNA is repressed in tumor relative to normal tissue. In most cancer types FTLP16 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

THCA, COAD, and LUSC are the cancer types where FTLP16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FTLP16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	All	−0.418	<.001	7	view →
COAD	All	II,III,IV	+0.030	.048	2	view →
LUSC	All	All	+0.092	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: FTLP16 RNA expression & survival · all FTLP16 data types